Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $52.4444.

Several equities analysts recently weighed in on the company. Mizuho set a $50.00 price objective on Sutro Biopharma and gave the stock an “outperform” rating in a research report on Thursday, April 30th. Wall Street Zen cut Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, June 14th. Citigroup reissued an “outperform” rating on shares of Sutro Biopharma in a research report on Friday, April 17th. Lifesci Capital raised Sutro Biopharma to a “strong-buy” rating in a research report on Friday, May 1st. Finally, HC Wainwright boosted their price objective on Sutro Biopharma from $28.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, May 15th.

Hedge Funds Weigh In On Sutro Biopharma

Large investors have recently made changes to their positions in the business. Bridgeway Capital Management LLC increased its stake in Sutro Biopharma by 232.6% during the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after acquiring an additional 30,000 shares during the period. Invesco Ltd. increased its stake in Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after acquiring an additional 53,390 shares during the period. Cerity Partners LLC increased its stake in Sutro Biopharma by 169.9% during the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after acquiring an additional 66,372 shares during the period. Qube Research & Technologies Ltd bought a new position in Sutro Biopharma during the second quarter valued at about $82,000. Finally, State of Tennessee Department of Treasury bought a new position in Sutro Biopharma during the fourth quarter valued at about $86,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

NASDAQ STRO opened at $29.55 on Friday. Sutro Biopharma has a twelve month low of $6.74 and a twelve month high of $43.85. The stock has a market capitalization of $489.64 million, a PE ratio of -2.68 and a beta of 1.54. The stock has a 50-day simple moving average of $31.69 and a 200 day simple moving average of $22.30.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($2.94) earnings per share for the quarter, missing the consensus estimate of ($2.74) by ($0.20). The company had revenue of $14.52 million during the quarter, compared to analyst estimates of $8.89 million. As a group, equities research analysts forecast that Sutro Biopharma will post -9.29 EPS for the current fiscal year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.